BD 652234 - PowerLoc Safety Infusion Set Without Y-Injection Site, 22G x 0.75", 20/PK (Continental US Only)

BD 652234 - PowerLoc Safety Infusion Set Without Y-Injection Site, 22G x 0.75", 20/PK (Continental US Only)

The BD 652234 PowerLoc Safety Infusion Set is a sterile, single-use port-access device designed for accessing compatible surgically implanted vascular ports. The set features a 22-gauge non-coring needle with a 0.75-inch length and is configured without a Y-injection site, providing a streamlined direct fluid pathway for compatible infusion therapy and vascular-access procedures.

The PowerLoc system is designed for the administration of compatible fluids and medications, blood specimen collection, implanted port flushing, and power injection through appropriately rated vascular-access systems. The 22-gauge configuration provides a smaller needle profile for applications where moderate flow capability meets the requirements of the prescribed therapy.

The 0.75-inch needle length is intended for implanted ports positioned relatively close to the skin surface. Correct needle-length selection helps support complete septum access, stable positioning, effective dressing application, and appropriate patient comfort.

This configuration includes approximately 8-inch tubing, a Luer-lock connector, and an approximate priming volume of 0.3 mL. Because the set does not include a Y-injection site, it provides a direct pathway without an integrated secondary medication or fluid-access point.

An integrated sliding safety needle mechanism is designed to help reduce accidental needlestick exposure during port deaccessing. As the needle is withdrawn, the safety system helps protect the sharp point and supports safer handling before final disposal in an approved sharps container.

The PowerLoc platform features a compact, low-profile, lightweight design that supports dressing placement, access-site visibility, and routine implanted port management. BD 652234 is commercially packaged 20 per case for CIA Medical ordering.

Key Benefits

• 22-gauge non-coring needle supports access to compatible surgically implanted vascular ports.
• 0.75-inch needle length accommodates appropriately positioned superficial implanted ports.
• Smaller 22-gauge profile is suitable for applications where moderate flow capability meets clinical requirements.
• Power-injectable design supports compatible contrast-enhanced diagnostic imaging procedures.
• Maximum power-injection flow rate up to 2 mL per second when the complete vascular-access system is appropriately rated.
• Configuration without a Y-injection site provides a streamlined direct fluid pathway.
• Approximately 8-inch tubing provides practical working length for port-access procedures.
• Approximate 0.3 mL priming volume supports fluid-management planning.
• Luer-lock connection supports secure attachment to compatible infusion components.
• Non-coring needle design helps minimize unnecessary damage to compatible implanted port septa during appropriate access.
• Sliding safety needle mechanism helps reduce accidental sharps exposure during deaccessing.
• Winged hub supports controlled insertion, stabilization, and removal.
• Low-profile design helps facilitate appropriate dressing application.
• Small footprint supports visibility around the implanted port access site.
• Lightweight construction helps minimize unnecessary bulk at the access site.
• Adaptable for appropriate dual-lumen implanted port applications.
• Suitable for compatible medication administration, blood sampling, port maintenance, and power-injection workflows.
• 20-per-case packaging supports routine clinical inventory management.

Compatibility and Applications

The BD 652234 PowerLoc Safety Infusion Set is intended for use with compatible surgically implanted vascular-access ports designed to accept non-coring port-access needles.

Potential clinical applications include medication administration, antibiotic therapy, hydration, selected chemotherapy treatments, parenteral nutrition, blood specimen collection, implanted port flushing, long-term infusion therapy, and compatible contrast-media injection during diagnostic imaging procedures.

The 22-gauge configuration may be selected when a smaller needle profile and moderate flow capability meet the requirements of the prescribed therapy. Selection should consider medication or fluid characteristics, viscosity, desired flow rate, implanted port specifications, infusion equipment, power-injection requirements, and professional clinical judgment.

The 0.75-inch needle length is generally appropriate for implanted ports located relatively close to the skin surface. A needle that is too short may not completely access the port septum, while unnecessary additional needle length may affect stability, securement, and dressing placement.

Because BD 652234 does not include a Y-injection site, it provides a direct fluid pathway without an integrated secondary access point. This configuration may be appropriate when the planned therapy uses a single primary connection and does not require intermittent medication or fluid administration through a Y-site.

For power injection, the implanted port, PowerLoc needle, tubing, connectors, extension components, and every other device within the complete fluid pathway must be specifically rated for the intended procedure. The lowest-rated component determines the maximum allowable operating pressure and flow rate.

Compatibility should be confirmed with the exact implanted port model, septum design, tissue depth, prescribed therapy, infusion pump, power injector, connector system, dressing materials, and institutional vascular-access procedures.

Usage Guidelines

The BD 652234 should be used only by healthcare professionals trained and authorized to access implanted vascular ports. Current manufacturer instructions, aseptic technique, institutional procedures, and the implanted port manufacturer's directions should be followed throughout the procedure.

• Confirm the patient's identity, prescribed therapy, implanted port type, and power-injection status when applicable.
• Assess the location and depth of the implanted port before selecting the 0.75-inch needle.
• Verify that the 22-gauge configuration provides appropriate flow capability for the intended therapy or imaging procedure.
• Confirm that a configuration without a Y-injection site is appropriate for the planned clinical workflow.
• Inspect the sterile package for damage, punctures, moisture, contamination, or compromised integrity.
• Prepare the implanted port site according to institutional skin-antisepsis and sterile-access procedures.
• Prime the complete fluid pathway with an approved solution before accessing the implanted port.
• Remove air completely from the tubing before connection to the vascular-access system.
• Stabilize the implanted port and insert the non-coring needle perpendicular to the septum using an approved technique.
• Advance the needle carefully until appropriate access to the port reservoir is achieved.
• Verify correct needle placement according to institutional policy, including aspiration for blood return when clinically appropriate.
• Flush the implanted port according to current manufacturer instructions and facility protocol.
• Position and secure the tubing to minimize pulling, twisting, pressure, and dressing disruption.
• Apply an appropriate sterile dressing while maintaining access-site visibility.
• Monitor the access site for pain, swelling, redness, leakage, displacement, or other abnormalities throughout therapy.
• Confirm power-injection eligibility before connecting the system to a power injector.
• Do not exceed 2 mL per second or the lower operating limit of any component within the complete vascular-access system.
• After therapy, flush and lock the implanted port according to the prescribed protocol.
• Stabilize the port while withdrawing the needle and activating the safety mechanism.
• Confirm that the safety feature has fully engaged before further handling.
• Dispose of the used device immediately in an approved sharps container.

Stop the procedure and assess the vascular-access system if unexpected resistance occurs during flushing, expected blood return cannot be obtained, the patient experiences unusual discomfort, or swelling, leakage, displacement, or another abnormality develops at the implanted port site.

Certifications and Safety Standards

The BD 652234 PowerLoc Safety Infusion Set is intended for professional medical use within established vascular-access, infusion-therapy, diagnostic imaging, infection-prevention, and occupational safety programs.

The device should be incorporated into facility procedures addressing implanted port assessment, hand hygiene, sterile preparation, skin antisepsis, port access, infusion administration, dressing management, power injection, deaccessing, and sharps disposal.

The integrated sliding safety needle mechanism is designed to help reduce accidental needle exposure during removal from an implanted vascular port. Correct safety activation should be confirmed before the used device is handled, transported, or discarded.

The safety feature supports needlestick-prevention practices but does not replace appropriate clinician training, personal protective equipment, safe sharps handling, exposure-control procedures, or immediate disposal in an approved sharps container.

The non-coring needle should be selected according to patient anatomy, implanted port depth, prescribed therapy, required flow characteristics, and current manufacturer instructions.

Healthcare organizations should review current manufacturer documentation for applicable FDA status, UDI information, sterilization method, material composition, natural rubber latex information, DEHP information, shelf life, pressure limitations, warnings, precautions, contraindications, and other product-specific regulatory requirements.

Comparison with Competitors

Compared with conventional implanted port needles without integrated safety technology, the BD PowerLoc system incorporates a safety mechanism designed to help reduce accidental sharps exposure during port deaccessing and disposal.

Compared with PowerLoc configurations containing a Y-injection site, BD 652234 provides a direct fluid pathway without an integrated secondary access point. This may simplify the tubing configuration when secondary medication or fluid administration through a Y-site is not required.

Compared with non-power-injectable port-access devices, the PowerLoc platform supports compatible power-injection procedures when used with an appropriately rated implanted port and complete vascular-access system.

Compared with 19-gauge and 20-gauge PowerLoc configurations, the 22-gauge needle provides a smaller external profile but lower maximum power-injection flow capability. The 22-gauge configuration supports up to 2 mL per second, while larger-gauge PowerLoc options may support higher flow requirements.

Compared with 1-inch and 1.5-inch access needles, the 0.75-inch configuration provides a lower access profile for implanted ports positioned closer to the skin surface. Correct needle-length selection supports complete septum access, device stability, securement, and effective dressing placement.

Alternative safety infusion sets may vary in gauge, needle length, power-injection capability, tubing length, priming volume, safety activation method, connection type, Y-site availability, and package quantity. BD 652234 combines a 22-gauge, 0.75-inch non-coring needle with approximately 8-inch tubing, 0.3 mL priming volume, Luer-lock connection, integrated safety technology, a direct no-Y-site configuration, and power-injection capability up to 2 mL per second.

Typical User Profile and Application Scenarios

The BD 652234 PowerLoc Safety Infusion Set is intended for trained healthcare professionals responsible for accessing and managing implanted vascular ports. Typical users include infusion nurses, oncology nurses, radiology nurses, vascular-access specialists, physicians, advanced practice clinicians, and other qualified healthcare personnel.

Common use environments include hospitals, oncology centers, outpatient infusion clinics, diagnostic imaging departments, ambulatory treatment centers, emergency departments, specialty practices, and other healthcare facilities where implanted vascular ports are routinely accessed.

The product may be selected for patients whose implanted port can be appropriately accessed with a 0.75-inch needle and whose prescribed treatment or diagnostic procedure is compatible with a 22-gauge access device.

Typical application scenarios include medication infusion, antibiotic therapy, hydration, selected chemotherapy treatments, parenteral nutrition, blood specimen collection, routine implanted port maintenance, and compatible power-injection procedures during diagnostic imaging.

The configuration without a Y-injection site is particularly relevant for clinical workflows using a direct primary connection that do not require an integrated secondary medication or fluid-access point within the tubing.

Best Practices for Use and Maintenance

The BD 652234 is a sterile, single-use medical device. Best practices focus on proper storage, accurate product selection, sterile preparation, implanted port access, site monitoring, power-injection verification, safety activation, and disposal.

• Store unopened sets according to current manufacturer-recommended environmental conditions.
• Protect packages from moisture, excessive temperatures, crushing, punctures, and contamination.
• Rotate inventory according to expiration dates and facility stock-control procedures.
• Verify the BD 652234 or manufacturer SKU 0652234 before opening the package.
• Confirm the 22-gauge size, 0.75-inch needle length, and configuration without a Y-injection site.
• Assess the patient's tissue depth and implanted port position before selecting the needle length.
• Confirm that the prescribed therapy and required flow characteristics are appropriate for a 22-gauge access device.
• Use strict aseptic technique during preparation, priming, insertion, connection, and dressing application.
• Prime the complete fluid pathway before accessing the implanted vascular port.
• Consider the approximately 0.3 mL priming volume when precise fluid management is clinically important.
• Stabilize the implanted port during both needle insertion and removal.
• Position the tubing to minimize pulling, twisting, or pressure at the access site.
• Monitor the implanted port site and tubing connections throughout therapy.
• Verify that the entire vascular-access system is appropriately rated before any power-injection procedure.
• Do not exceed 2 mL per second or the lowest pressure or flow-rate limit of any component within the complete system.
• Do not bend, cut, modify, repair, or otherwise alter the infusion set.
• Do not reuse, clean, resterilize, or reprocess the single-use device.
• Confirm complete safety activation immediately after needle withdrawal.
• Place the protected device directly into an approved sharps container.

Regulatory and Safety Information

The BD 652234 PowerLoc Safety Infusion Set should be used only by appropriately trained healthcare professionals and only for applications consistent with current manufacturer labeling, implanted port instructions, professional clinical judgment, and institutional policy.

Before use, verify the product identity, 22-gauge size, 0.75-inch needle length, no-Y-site configuration, sterile package integrity, expiration date, and compatibility with the implanted vascular port. Do not use a device that is expired, damaged, contaminated, or supplied in compromised packaging.

The set should not be used for power injection unless the implanted port and every component within the complete fluid pathway are specifically rated for the intended procedure. Permitted pressure, flow rate, contrast-media characteristics, and other operating conditions must be confirmed before use.

BD identifies manufacturer SKU 0652234 with a maximum power-injection flow rate of 2 mL per second. The lowest-rated component within the complete vascular-access system determines the actual maximum allowable operating limit.

Incorrect needle-length selection, incomplete septum access, excessive pressure, needle displacement, or improper securement may contribute to infiltration, extravasation, leakage, tissue injury, implanted port damage, interrupted therapy, or other complications.

Because BD 652234 does not include a Y-injection site, it does not provide an integrated secondary access point within the tubing. Clinical teams should confirm that a direct fluid pathway meets the requirements of the planned therapy before use.

The integrated safety mechanism should be activated according to current manufacturer instructions. The device remains a contaminated sharp following deaccessing and should be discarded immediately in an approved sharps container.

BD lists manufacturer SKU 0652234 as 20 per shelfpack, while CIA Medical sells the corresponding configuration as 20 per case. Purchasing personnel should confirm current availability, storage requirements, shipping eligibility, order quantities, and applicable return conditions before purchasing.

How to Order

Select the BD 652234 - PowerLoc Safety Infusion Set without Y-Injection Site, 22G x 0.75" and add it to your cart. Complete checkout with your preferred shipping and payment options. For bulk orders, quotes, or further assistance, contact CIA Medical customer service at (312)275-5850 or use the contact form on this page.